KAMADA LTDKMDAEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Kamada Ltd. is a global biopharmaceutical company specializing in the research, manufacturing, and commercialization of specialty pharmaceuticals derived from human plasma.
Revenue
$37.4M
Gross Profit
$14.4M
Operating Profit
$2.6M
Net Profit
$1.8M
Gross Margin
38.6%
Operating Margin
7.0%
Net Margin
4.8%
YoY Growth
58.7%
EPS
$0.04
KAMADA LTD Q2 FY2023 Financial Summary
KAMADA LTD reported revenue of $37.4M (up 58.7% YoY) for Q2 FY2023, with a net profit of $1.8M (up 146.2% YoY) (4.8% margin). Cost of goods sold was $23.0M, operating expenses totaled $11.8M.
Key Financial Metrics
| Total Revenue | $37.4M |
|---|---|
| Net Profit | $1.8M |
| Gross Margin | 38.6% |
| Operating Margin | 7.0% |
| Report Period | Q2 FY2023 |
KAMADA LTD Quarterly Revenue & Net Profit History
KAMADA LTD results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $47.0M | +12.6% | $5.3M | 11.3% |
| Q2 FY2025 | $44.8M | +5.4% | $7.4M | 16.5% |
| Q1 FY2025 | $44.0M | +16.6% | $4.0M | 9.0% |
| Q3 FY2024 | $41.7M | +10.0% | $3.9M | 9.3% |
| Q2 FY2024 | $42.5M | +13.4% | $4.4M | 10.4% |
| Q1 FY2024 | $37.7M | +122778.5% | $2.4M | 6.3% |
| Q3 FY2023 | $37.9M | +117645.3% | $3.2M | 8.5% |
| Q2 FY2023 | $37.4M | +58.7% | $1.8M | 4.8% |
Income Statement
| Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $37.4M | $37.9M | $37.7M | $42.5M | $41.7M | $44.0M | $44.8M | $47.0M |
| YoY Growth | 58.7% | 117645.3% | 122778.5% | 13.4% | 10.0% | 16.6% | 5.4% | 12.6% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $314.4M | $337.1M | $343.2M | $351.0M | $351.2M | $375.1M | $368.2M | $377.2M |
| Liabilities | $137.6M | $98.7M | $92.0M | $99.9M | $95.9M | $123.1M | $108.2M | $112.0M |
| Equity | $176.8M | $238.4M | $251.2M | $251.2M | $255.3M | $252.0M | $260.0M | $265.2M |
Cash Flow
| Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $1.8M | $921000 | $1.0M | $14.0M | $22.2M | $-513000 | $8.0M | $10.4M |